Why is Windlas Biotech falling/rising?

As of 28-Aug, Windlas Biotech Ltd is currently priced at 995.10, reflecting an increase of 7.1, or 0.72%. Today's price summary indicates that the stock has outperformed its sector by 1.56% and has gained after six consecutive days of decline. Despite opening with a loss of 3.85% and touching an intraday low of Rs 950, the stock remains higher than its 20-day, 50-day, 100-day, and 200-day moving averages, although it is lower than the 5-day moving average. The company has demonstrated strong financial performance, with record net sales and profits in the latest quarter, and has consistently generated returns over the past three years, outperforming the BSE500 index. However, a notable decline in investor participation, with delivery volume dropping by 40.18% against the 5-day average, may be a concern.
In the broader market context, Windlas Biotech's short-term performance shows a 1.06% increase over the past month, contrasting with a 1.00% decline in the Sensex, indicating relative strength against the benchmark. Year-to-date, the stock has underperformed with a decline of 3.71%, while the Sensex has gained 2.48%. Despite these fluctuations, the company's low debt-to-equity ratio and fair valuation suggest stability, while its majority ownership by promoters may provide confidence to investors. Overall, the stock's recent rise can be attributed to positive quarterly results and a trend reversal after a period of decline, although the drop in trading volume raises questions about future momentum.